Changpeng Chai

Dr. Changpeng Chai


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
CCChangpeng Chai
Changpeng Chai
PJPengfei Ji
Pengfei Ji
HXHao Xu
Hao Xu
HTHuan Tang
Huan Tang
ZWzhengfeng wang
zhengfeng wang
ZWzhou wence
zhou wence
Cancer organoids generated from 3D in vitro cell cultures have contributed to the study of drug resistance. Maintenance of genomic and transcriptomic similarity between organoids and parental cancer allows organoids to have the ability of accurate prediction in drug resistance testing. Protocols of establishing therapy-sensitive and therapy-resistant organoids are concluded in two aspects, which are generated directly from respective patients' cancer and by induction of anti-cancer drug. Genomic and transcriptomic analyses and gene editing have been applied to organoid studies to identify key targets in drug resistance and FGFR3, KHDRBS3, lnc-RP11-536 K7.3 and FBN1 were found to be key targets. Furthermore, mechanisms contributing to resistance have been identified, including metabolic adaptation, activation of DNA damage response, defects in apoptosis, reduced cellular senescence, cellular plasticity, subpopulation interactions and gene fusions. Additionally, cancer stem cells (CSCs) have been verified to be involved in drug resistance utilizing organoid technology. Reversal of drug resistance can be achieved by targeting key genes and CSCs in cancer organoids. In this review, we summarize applications of organoids to cancer drug resistance research, indicating prospects and limitations.

15 January 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
LSLi Shang
Li Shang
GZGuoqiang Zhang
Guoqiang Zhang
XLXiaohong Li
Xiaohong Li
XZXu Zhao
Xu Zhao
ASAxi Shi
Axi Shi
XLXun Li
Xun Li
Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly linked to systemic metabolic disturbances and features a lipid-driven cascade that promotes hepatic inflammation and fibrosis. Choline insufficiency contributes to disease advancement by altering phospholipid turnover and redox homeostasis; however, its spatial and temporal regulatory roles throughout MASLD progression remain insufficiently defined. A 10-week high-fat, choline-deficient (HFCD) mouse model was established, and liver pathology was evaluated at weeks 6, 8, and 10. Time-resolved assessments combined untargeted metabolomics, magnetic resonance imaging–proton density fat fraction (MRI-PDFF), serum biochemistry, histological staining, immunofluorescence, and transmission electron microscopy to characterize dynamic alterations in lipid metabolism, redox status, inflammation, and fibrogenesis. The HFCD diet produced a clear temporal sequence of liver injury. Steatosis, phosphatidylcholine depletion, and early antioxidant loss appeared by week 6. By week 8, mitochondrial structural damage and pronounced cytokine elevation were evident. At week 10, collagen deposition and α-SMA activation signaled fibrotic progression. Metabolomics indicated significant disruptions in pathways related to ATP-binding cassette (ABC) transporters, one-carbon metabolism, and the tricarboxylic acid (TCA) cycle. Using integrated analytical strategies, this study suggests that choline deficiency may be associated with a time-dependent pathological cascade in MASLD, beginning with phospholipid destabilization and extending to altered mitochondria–endoplasmic reticulum crosstalk at mitochondria-associated membranes, alongside amplified oxidative–inflammatory responses, which collectively may contribute to progressive fibrogenesis as the disease advances.

1 September 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HTHuan Tang
Huan Tang
XMXin Miao
Xin Miao
YSYuanhui Su
Yuanhui Su
YZYanlong Zhang
Yanlong Zhang
CYCheng Yu
Cheng Yu
HXHao Xu
Hao Xu
The scarcity of preclinical models for colon cancer liver metastasis significantly impedes research progress, underscoring the critical need to establish s

6 April 2026 in BMC Gastroenterology
Verified
Journal Article
Open access
YSYulan Song
Yulan Song
RRRongwei Ren
Rongwei Ren
RLRuxuan Li
Ruxuan Li
MZMingyang Zou
Mingyang Zou
YPYixin Pan
Yixin Pan
CCChangpeng Chai
Changpeng Chai
Esophagogastric variceal bleeding (EGVB) is a life-threatening complication of decompensated cirrhosis that imposes a substantial inpatient economic burden. However, the specific determinants and cost composition of EGVB hospitalization remain poorly defined in China. We retrospectively analyzed 122 patients admitted with EGVB between April 2019 and July 2023 at the First Hospital of Lanzhou University. Demographic, clinical, and itemized cost data were retrieved from electronic records. Total hospitalization cost was log-transformed and examined by stepwise multiple linear regression to identify independent predictors. K-means clustering was used to explore patterns in cost composition. The median cost was CNY 34,744. Surgical type, length of stay, and insurance category were the strongest predictors of total cost (R² = 0.81, P < 0.01). Western medication and procedural expenses constituted the largest cost components, while hospital duration and discharge status had smaller effects. In patients with EGVB secondary to decompensated cirrhosis, surgical approach and insurance coverage drive inpatient expenditure. Optimizing clinical pathways and financial policies could reduce the direct medical burden and enhance value-based liver care in China.